Oncology (all articles)
Best Practice Recommendations: Management of adults and children receiving CAR T-cell therapy.
12 Jan, 2022 | 08:31h | UTC
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.
11 Jan, 2022 | 02:30h | UTC
RCT: In premenopausal women with breast cancer, gonadotropin-releasing hormone analogs may preserve ovarian function against chemotherapy-induced gonadotoxic effects.
11 Jan, 2022 | 02:26h | UTCEffects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/gymbKT9GWZ pic.twitter.com/OUOlIwPSsq
— JAMA Oncology (@JAMAOnc) December 30, 2021
RCT: In patients presenting with metastatic breast cancer, early locoregional therapy for the primary site did not improve survival or quality of life.
11 Jan, 2022 | 02:29h | UTCEarly Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) – Journal of Clinical Oncology (link to abstract – $ for full-text)
M-A of two randomized trials: Among men with high-risk non-metastatic prostate cancer, adding abiraterone and prednisolone to standard androgen-deprivation therapy was associated with improved 6-year metastasis-free survival (82% vs. 69% in the control group).
8 Jan, 2022 | 22:42h | UTCAbiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol – The Lancet (link to abstract – $ for full-text)
Related Audio: Key messages of the recent report from the STAMPEDE trial platform
Systematic Review: Active surveillance for clinically localized prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy.
8 Jan, 2022 | 22:41h | UTC
Commentary on Twitter
Systematic Review of AS for Clinically Localised PCa to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategyhttps://t.co/U9mA5KqStX@Dr_Willemse @thomas_b_lam pic.twitter.com/j6dgTaqaZs
— European Urology (@EUplatinum) January 3, 2022
Meta-analysis (mostly of observational studies): In patients undergoing pancreaticoduodenectomy, routine nasogastric decompression is associated with increased rates of delayed gastric emptying, major complications, and longer length of stay compared to no routine nasogastric decompression.
8 Jan, 2022 | 22:44h | UTCRelated Study: Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial – JAMA Surgery
Commentary on Twitter
Nasogastric decompression after pancreaticoduodenectomy 🐘 what is your practice?!
👎 Routine NG tube associated with ⬆️ rates of DGE, major complications and longer length of stay
✅ @ErasSociety policies should be standard
New meta analys on @BjsOpen https://t.co/OStyWOfrPV pic.twitter.com/tuwjPYFWia
— Giovanni Marchegiani (@Gio_Marchegiani) January 3, 2022
RCT: Postoperative radiotherapy (PORT) did not increase disease-free survival compared with no PORT in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement.
8 Jan, 2022 | 22:38h | UTCPostoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Post-Operative Radiotherapy Not Tied to Better Disease-Free Survival in NSCLC – MedPage Today (free registration required)
Prevention of Chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes.
17 Dec, 2021 | 08:32h | UTCPrevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes – Drugs & Aging (if the link is paywalled, try this one)
M-A: Adjuvant chemotherapy for muscle-invasive bladder cancer.
17 Dec, 2021 | 08:28h | UTC
Commentary on Twitter
Adjuvant Chemotherapy for MIBC: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trialshttps://t.co/EZzsMirWAz
"Cisplatin-based adjuvant chemotherapy is a valid option for improving outcomes for muscle-invasive bladder cancer" pic.twitter.com/dIB1aqqNHn
— European Urology (@EUplatinum) November 26, 2021
Review: Immunotherapies for hepatocellular carcinoma.
14 Dec, 2021 | 08:47h | UTCImmunotherapies for hepatocellular carcinoma – Nature Reviews Clinical Oncology (free for a limited period – if the link is paywalled, try this one)
Colorectal cancer incidence, mortality, tumor characteristics, and treatment before and after the introduction of the fecal immunochemical testing-based screening program in the Netherlands: a population-based study.
13 Dec, 2021 | 08:50h | UTCColorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Breekveldt et al – #Colorectalcancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the FIT-based #screening programme in the #Netherlands: a population-based studyhttps://t.co/nW9SVAhRxE#GITwitter #crcsm pic.twitter.com/GGRF9Az0tg
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) November 23, 2021
Review: Endometrial cancer.
13 Dec, 2021 | 08:43h | UTCEndometrial cancer – Nature Reviews Disease Primers (free for a limited period – if the link is paywalled, try this one)
Infographic: Endometrial cancer (free for a limited period – if the link is paywalled, try this one)
Non-inferiority randomized trial showed radiotherapy can be safely omitted in many children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma.
10 Dec, 2021 | 10:04h | UTC
Systematic Review: Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer.
9 Dec, 2021 | 10:08h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/ccaneloa/status/1464655542010494981
M-A: Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
8 Dec, 2021 | 09:48h | UTC
Commentary on Twitter
This meta-analysis of RCTs shows immune checkpoint inhibitors are associated with demonstrated the superior efficacy and safety of versus standard systemic therapies in patients with unresectable hepatocellular carcinoma. https://t.co/fJdFng69qH
— JAMA Network Open (@JAMANetworkOpen) December 6, 2021
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.
8 Dec, 2021 | 09:45h | UTC
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
8 Dec, 2021 | 09:47h | UTC
Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.
7 Dec, 2021 | 08:47h | UTC
Review | Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification.
5 Dec, 2021 | 23:40h | UTCVideo: Radiation Therapy and Cardiovascular Disease | JACC: CardioOncology Author Discussion
Related:
Radiation‐induced cardiovascular disease: review of an underrecognized pathology.
Short review: How to diagnose and manage radiation therapy cardiotoxicity
Cohort Study: Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients with Lung Cancer
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
5 Dec, 2021 | 23:09h | UTCInvited Commentary: Burden of cancer in adolescents and young adults – The Lancet Oncology
RCT: Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone vs. Ipilimumab in patients with advanced melanoma.
5 Dec, 2021 | 23:07h | UTCEditorial: CheckMate-067: Raising the Bar for the Next Decade in Oncology – Journal of Clinical Oncology
Original Study: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma
RCT: Cytoreductive surgery for relapsed ovarian cancer.
2 Dec, 2021 | 09:51h | UTC
RCT: 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.
2 Dec, 2021 | 09:49h | UTC21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among postmenopausal women with HR–positive, HER2-negative breast cancer, 1-3 positive lymph nodes, and a 21-gene recurrence score of 25 or lower, 5-year invasive disease–free survival was similar whether they received endocrine or chemoendocrine therapy. https://t.co/aZLXBvSHHl pic.twitter.com/EBVnMkGHx4
— NEJM (@NEJM) December 2, 2021
Integrative oncology: Addressing the global challenges of cancer prevention and treatment.
1 Dec, 2021 | 08:34h | UTCCommentary: Addressing the Global Challenges of Cancer Prevention and Treatment – The ASCO Post